HSPA1A and fatty liver disease: Our findings suggest that HSP70 promotes lipogenesis in HepG2 cells, making it an attractive drug target, as pharmacological manipulation of Hsp70 could have potential uses in the treatment of metabolic disorders such as diabetes and liver steatosis, among others.